TY - JOUR
T1 - Human papillomavirus (HPV) 16 and the prognosis of head and neck cancer in a geographical region with a low prevalence of HPV infection
AU - López, Rossana Verónica Mendoza
AU - Levi, José Eduardo
AU - Eluf-Neto, José
AU - Koifman, Rosalina Jorge
AU - Koifman, Sergio
AU - Curado, Maria Paula
AU - Michaluart, Pedro
AU - Figueiredo, David Livingstone Alves
AU - Saggioro, Fabiano Pinto
AU - De Carvalho, Marcos Brasilino
AU - Kowalski, Luiz Paulo
AU - Abrahão, Márcio
AU - De Góis-Filho, Francisco
AU - Tajara, Eloiza Helena
AU - Waterboer, Tim
AU - Boffetta, Paolo
AU - Brennan, Paul
AU - Wünsch-Filho, Victor
N1 - Funding Information:
Acknowledgments This work was supported by Fundac¸ão de Amparo à Pesquisa do Estado de São Paulo (FAPESP) [10/50733-6; 09/52031-1 and 04/12054-9] and by the European Commission [IC18-CT97-0222].
PY - 2014/4
Y1 - 2014/4
N2 - Background: The role of human papillomavirus (HPV) on head and neck squamous cell carcinoma (HNSCC) survival in regions with low HPV prevalence is not yet clear. We evaluated the HPV16 infection on survival of HNSCC Brazilian patient series. Methods: This cohort comprised 1,093 HNSCC cases recruited from 1998 to 2008 in four Brazilian cities and followed up until June 2009. HPV16 antibodies were analyzed by multiplex Luminex assay. In a subset of 398 fresh frozen or paraffin blocks of HNSCC specimens, we analyzed for HPV16 DNA by L1 generic primer polymerase chain reaction. HNSCC survival according to HPV16 antibodies was evaluated through Kaplan-Meier method and Cox regression. Results: Prevalence of HPV16 E6 and E6/E7 antibodies was higher in oropharyngeal cancer than in other head and neck tumor sites. HPV16 DNA positive in tumor tissue was also higher in the oropharynx. Seropositivity for HPV16 E6 antibodies was correlated with improved HNSCC survival and oropharyngeal cancer. The presence of HPV16 E6/E7 antibodies was correlated with improved HNSCC survival and oropharyngeal cancer survival. The death risk of oropharyngeal squamous cell carcinoma patients HPV16 E6/E7 antibodies positive was 78 % lower than to those who test negative. Conclusion: Oropharyngeal squamous cell carcinoma is less aggressive in the HPV16 E6/E7 positive serology patients. HPV16 E6/E7 antibody is a clinically sensible surrogate prognostic marker of oropharyngeal squamous cell carcinoma.
AB - Background: The role of human papillomavirus (HPV) on head and neck squamous cell carcinoma (HNSCC) survival in regions with low HPV prevalence is not yet clear. We evaluated the HPV16 infection on survival of HNSCC Brazilian patient series. Methods: This cohort comprised 1,093 HNSCC cases recruited from 1998 to 2008 in four Brazilian cities and followed up until June 2009. HPV16 antibodies were analyzed by multiplex Luminex assay. In a subset of 398 fresh frozen or paraffin blocks of HNSCC specimens, we analyzed for HPV16 DNA by L1 generic primer polymerase chain reaction. HNSCC survival according to HPV16 antibodies was evaluated through Kaplan-Meier method and Cox regression. Results: Prevalence of HPV16 E6 and E6/E7 antibodies was higher in oropharyngeal cancer than in other head and neck tumor sites. HPV16 DNA positive in tumor tissue was also higher in the oropharynx. Seropositivity for HPV16 E6 antibodies was correlated with improved HNSCC survival and oropharyngeal cancer. The presence of HPV16 E6/E7 antibodies was correlated with improved HNSCC survival and oropharyngeal cancer survival. The death risk of oropharyngeal squamous cell carcinoma patients HPV16 E6/E7 antibodies positive was 78 % lower than to those who test negative. Conclusion: Oropharyngeal squamous cell carcinoma is less aggressive in the HPV16 E6/E7 positive serology patients. HPV16 E6/E7 antibody is a clinically sensible surrogate prognostic marker of oropharyngeal squamous cell carcinoma.
KW - Head and neck cancer
KW - Human papillomavirus
KW - Prevalence
KW - Prognosis
KW - Serology
UR - http://www.scopus.com/inward/record.url?scp=84896091589&partnerID=8YFLogxK
U2 - 10.1007/s10552-014-0348-8
DO - 10.1007/s10552-014-0348-8
M3 - Article
C2 - 24474236
AN - SCOPUS:84896091589
SN - 0957-5243
VL - 25
SP - 461
EP - 471
JO - Cancer Causes and Control
JF - Cancer Causes and Control
IS - 4
ER -